Beginning points of Due Diligence for Athersys (ATHX) I am long the stock from $1.24. My Short Term catalyst Price Target opinion is $1.55 to $1.75, and $2.75 based on if positive Phase II data is reported. Multiple 2013 Catalysts…
Tag: trading
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers (Video)
Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers commentary. YouTube Video, enjoy!
Neptune’s Bounce Should Continue: $3 in range
Originally posted at www.biomedreports.com Updated by StockMatusow.com Twitter @BioMedReports @ScottMatusow Neptune Technologies & Bioressources announced they will hold a conference call on Thursday, January 17th at 4:30 EST. The reason given for the call will be to discuss the third…
BioLineRx: Big Catalyst Upcoming With Potential Multi Billion Dollar Schizophrenia Drug
BioLineRx’s (BLRX) engages in identifying, in-licensing, and developing therapeutic candidates. Its lead clinical therapeutic candidate under development is BL-1020, which is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients. BL-1020 is an orally available, first in…
EDAP: An Undervalued Company With An Alternative Treatment For Prostate Cancer
In doing some fresh scans for 2013, I found a company that has a very small market cap of only $38 million but competes in the very large market of prostate cancer. EDAP TMS SA (EDAP) looks like a very…
BioTech wrap up for December 21st $ALXA $FOLD
$ALXA and $FOLD Commentary, Merry Christmas and a happy new year to everyone!
Strong Small Cap Biopharma Catalyst Trades And Investments For Consideration
Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
ArQule: A Strong Speculation BioPharma Poised For A Quick Move Up On Near Term Catalyst
ArQule (NASDAQ: ARQL) ArQule engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product candidate Tivantinib (ARQ 197) is an inhibitor of the c-Met receptor tyrosine kinase, which is in Phase…
Alert: I bought ArQule Inc. $ARQL
ArQule Inc. (ARQL) Price: $2.86 Market Cap: $178.30M My price target opinion into January 13, $4.00 Catalyst: Tivantinib ArQule has advanced into Phase 3 clinical development with its lead product, tivantinib (ARQ 197), an orally available, small molecule that inhibits…
Osiris Therapeutics (OSIR) Catalyst Trade Thesis
Osiris Therapeutics (OSIR) Osiris expects to have data in hand (final data collection date for primary outcome measure) by the end of this year for the Phase III evaluation of Prochymal (remestemcel-L), which is an adult human stem cells treatment…
